187 related articles for article (PubMed ID: 28189168)
1. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.
Barton-Burke M; Ciccolini K; Mekas M; Burke S
Nurs Clin North Am; 2017 Mar; 52(1):83-113. PubMed ID: 28189168
[TBL] [Abstract][Full Text] [Related]
2. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
3. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
Lacouture ME; Anadkat MJ; Bensadoun RJ; Bryce J; Chan A; Epstein JB; Eaby-Sandy B; Murphy BA;
Support Care Cancer; 2011 Aug; 19(8):1079-95. PubMed ID: 21630130
[TBL] [Abstract][Full Text] [Related]
4. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
5. [Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors].
Jiang L; Xiao K; Long H
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jan; 56(1):87-94. PubMed ID: 35092997
[TBL] [Abstract][Full Text] [Related]
6. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
7. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
Ehmann LM; Heinemann V; Wollenberg A
Internist (Berl); 2011 Nov; 52(11):1359-64. PubMed ID: 21796420
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
9. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Lacouture ME; Maitland ML; Segaert S; Setser A; Baran R; Fox LP; Epstein JB; Barasch A; Einhorn L; Wagner L; West DP; Rapoport BL; Kris MG; Basch E; Eaby B; Kurtin S; Olsen EA; Chen A; Dancey JE; Trotti A
Support Care Cancer; 2010 Apr; 18(4):509-22. PubMed ID: 20145956
[TBL] [Abstract][Full Text] [Related]
10. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.
Amitay-Laish I; David M; Stemmer SM
Oncologist; 2010; 15(9):1002-8. PubMed ID: 20709888
[TBL] [Abstract][Full Text] [Related]
11. Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.
Ke YT; Kuo CC
Adv Skin Wound Care; 2017 Jan; 30(1):27-34. PubMed ID: 27984271
[TBL] [Abstract][Full Text] [Related]
12. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
13. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
14. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.
Mitchell EP; Perez-Soler R; Van Cutsem E; Lacouture ME
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):4-9. PubMed ID: 18154212
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
16. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.
Peuvrel L; Bachmeyer C; Reguiai Z; Bachet JB; André T; Bensadoun RJ; Bouché O; Ychou M; Dréno B
Support Care Cancer; 2012 May; 20(5):909-21. PubMed ID: 22361824
[TBL] [Abstract][Full Text] [Related]
17. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
18. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Gisondi P; Geat D; Mattiucci A; Lombardo F; Santo A; Girolomoni G
Dermatology; 2021; 237(6):929-933. PubMed ID: 33508823
[TBL] [Abstract][Full Text] [Related]
20. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]